Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Ovarian Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Fallopian Tube Neoplasms 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Osteosarcoma 1Neoplasms 1Meningeal Neoplasms 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Giant Cell Tumor of Bone 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

trametinib 3pembrolizumab 2lenvatinib 2dabrafenib 2Paclitaxel 2Nivolumab 2selpercatinib 1fludarabine 1cobimetinib 1atezolizumab 1aldesleukin 1Vemurafenib 1Taxes 1Radiotherapy, Intensity-Modulated 1Ipilimumab 1Immunoglobulin G 1Disulfides 1Cyclophosphamide 1CTLA-4 Antigen 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Carcinoma, Anaplastic × aldesleukin × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡